Genetic targeting or pharmacologic inhibition of NADPH oxidase Nox4 provides renoprotection in long-term diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 25, Issue 6, 2014, Pages 1237-1254

  Jha, Jay C ^a   Gray, Stephen P ^a   Barit, David ^a   Okabe, Jun ^a   El Osta, Assam ^a   Namikoshi, Tamehachi ^a,c   Thallas Bonke, Vicki ^a   Wingler, Kirstin ^d   Szyndralewiez, Cedric ^e   Heitz, Freddy ^e   Touyz, Rhian M ^f,g   Cooper, Mark E ^a,b   Schmidt, Harald H H W ^d   Jandeleit Dahm, Karin A ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e GENKYOTEX SA   (Switzerland)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GKT 137831; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDOREDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SCLEROPROTEIN; SUPEROXIDE; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; ENZYME INHIBITOR; GKT137831; GLUCOSE; NOX1 PROTEIN, HUMAN; NOX4 PROTEIN, HUMAN; NOX4 PROTEIN, MOUSE; OXIDOREDUCTASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOWN REGULATION; ENZYME INHIBITION; GENE DELETION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; KIDNEY STRUCTURE; MACROPHAGE; METABOLIC REGULATION; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; EXTRACELLULAR MATRIX; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; TRANSFORMED CELL LINE;

ALBUMINURIA; ANIMALS; APOLIPOPROTEINS E; CELL LINE, TRANSFORMED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; GENE SILENCING; GLUCOSE; HUMANS; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; NADH, NADPH OXIDOREDUCTASES; NADPH OXIDASE; PODOCYTES; PYRAZOLES; PYRIDINES; REACTIVE OXYGEN SPECIES;

EID: 84901835198     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013070810     Document Type: Article

References (61)

1. MolitchME, DeFronzo RA, FranzMJ, KeaneWF,Mogensen CE, Parving HH, Steffes MW; American Diabetes Association: Nephropathy in diabetes. Diabetes Care 27[Suppl 1]: S79-S83, 2004
2. Calcutt NA, Cooper ME, Kern TS, Schmidt AM: Therapies for hyperglycaemia-induced diabetic complications: From animal models to clinical trials. Nat Rev Drug Discov 8: 417-429, 2009
3. Kakehi T, Yabe-Nishimura C: NOX enzymes and diabetic complications. Semin Immunopathol 30: 301-314, 2008
4. Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A, Haneda M: Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 52: 2603-2614, 2003
5. SatohM, Fujimoto S, Haruna Y, Arakawa S, Horike H, KomaiN, Sasaki T, Tsujioka K, Makino H, Kashihara N: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288: F1144-F1152, 2005
6. Susztak K, Raff AC, Schiffer M, Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006
7. Sedeek M, Hébert RL, Kennedy CR, Burns KD, Touyz RM: Molecular mechanisms of hypertension: Role ofNox family NADPH oxidases. Curr Opin Nephrol Hypertens 18: 122-127, 2009
8. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM: Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 124: 191-202, 2013
9. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR: NADPH oxidases in the vasculature:Molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120: 254-291, 2008
10. Wingler K, Hermans JJ, Schiffers P, Moens A, Paul M, Schmidt HH: NOX1, 2, 4, 5: Counting out oxidative stress. Br J Pharmacol 164: 866-883, 2011
11. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H: Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46: 1428-1437, 2003
12. Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC, Cooper ME, Jandeleit-DahmKA: The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol 299: F528-F535, 2010
13. Ohshiro Y,Ma RC, Yasuda Y,Hiraoka-Yamamoto J, Clermont AC, Isshiki K, Yagi K, Arikawa E, Kern TS, King GL: Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 55: 3112-3120, 2006
14. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, Jandeleit-Dahm KA: NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127: 1888-1902, 2013
15. Block K, Gorin Y, Abboud HE: Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci U S A 106: 14385-14390, 2009
16. Geiszt M, Kopp JB, Várnai P, Leto TL: Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 97: 8010-8014, 2000
17. Gorin Y, Block K:Nox4 and diabetic nephropathy:With a friend like this, who needs enemies? Free Radic Biol Med 61C: 130-142, 2013
18. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, Hattori M, Sakaki Y, Sumimoto H: A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem276: 1417-1423, 2001
19. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE: Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280: 39616-39626, 2005
20. Babelova A, Avaniadi D, Jung O, Fork C, Beckmann J, Kosowski J, Weissmann N, Anilkumar N, Shah AM, Schaefer L, Schröder K, Brandes RP: Role of Nox4 in murine models of kidney disease. Free Radic Biol Med 53: 842-853, 2012
21. Nlandu Khodo S, Dizin E, Sossauer G, Szanto I, Martin PY, Feraille E, Krause KH, de Seigneux S: NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol 23: 1967-1976, 2012
22. Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, Molango S, Heitz F, Merlot C, Szyndralewiez C, Page P, Brenner DA: Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56: 2316-2327, 2012
23. CooperME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, KellyDJ,Gilbert RE: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239, 1999
24. Laurindo FR, Fernandes DC, Santos CX: Assessment of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation products. Methods Enzymol 441: 237-260, 2008
25. Chow FY, Nikolic-Paterson DJ,Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69: 73-80, 2006
26. Cooper ME, Mundel P, Boner G: Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 22: 393-398, 2002
27. Herman-EdelsteinM, ThomasMC, Thallas-Bonke V, SaleemM, Cooper ME, Kantharidis P: Dedifferentiation of immortalized human podocytes in response to transforming growth factor-b: A model for diabetic podocytopathy. Diabetes 60: 1779-1788, 2011
28. Chai Z, Dai A, Tu Y, Li J, Wu T, Wang Y, Hale LJ, Koentgen F, Thomas MC,CooperME:Genetic deletion ofCDA1 retards diabetes associated renal injury. J Am Soc Nephrol 24: 1782-1792, 2013
29. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA: Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: Role of advanced glycation end products. J AmSoc Nephrol 15: 2125-2138, 2004
30. Altenhöfer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, Ho H, Wingler K, Schmidt HH: The NOX toolbox: Validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci 69: 2327-2343, 2012
31. Wind S, Beuerlein K, Eucker T, Müller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, Wingler K: Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161: 885-898, 2010
32. Fujii M, Inoguchi T, Maeda Y, Sasaki S, Sawada F, Saito R, Kobayashi K, Sumimoto H, Takayanagi R: Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 72: 473-480, 2007
33. Ford BM, Eid AA, Göoz M, Barnes JL, Gorin YC, Abboud HE: ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. Am J Physiol Renal Physiol 305: F323-F332, 2013
34. Brosius FC: Susceptible mice: Identifying a diabetic nephropathy disease locus using a murine model. Kidney Int 78: 431-432, 2010
35. Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL:NAD(P)Hoxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol 21: 93-102, 2010
36. SedeekM, Callera G,Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, Hébert RL: Critical role of Nox4-basedNADPH oxidase in glucose-induced oxidative stress in the kidney: Implications in type 2 diabetic nephropathy.Am J Physiol Renal Physiol 299: F1348-F1358, 2010
37. Piwkowska A, Rogacka D, Audzeyenka I, JankowskiM, Angielski S:High glucose concentration affects the oxidant-antioxidant balance in cultured mouse podocytes. J Cell Biochem 112: 1661-1672, 2011
38. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094, 2002
39. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX: Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: Role of NADPH oxidase 4. Diabetes 59: 1528-1538, 2010
40. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, BaritD, Schwarz T,Geis C, Kraft P, Barthel K, SchuhmannMK,Herrmann AM, Meuth SG, Stoll G, Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, de Angelis MH, Jandeleit-Dahm K, Shah AM, Weissmann N, Schmidt HH: Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8: 8, 2010
41. Park HS, Chun JN, Jung HY, Choi C, Bae YS: Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res 72: 447-455, 2006
42. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, Matsumura T, Tokunaga H, Brownlee M, Araki E: Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: Potential role in diabetic nephropathy. Diabetes 52: 2570-2577, 2003
43. Nishikawa T, Edelstein D, Du XL, Yamagishi S,Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000
44. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS: Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285: R117-R124, 2003
45. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, FukunagaM, TamakiT, KiyomotoH, KohnoM,Shokoji T, KimuraS, Abe Y: The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 15: 306-315, 2004
46. Gurley SB, Coffman TM: The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 27: 144-152, 2007
47. Kobori H, Kamiyama M, Harrison-Bernard LM, Navar LG: Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy. J InvestigMed 61: 256-264, 2013
48. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, Delafontaine P, Chandrasekar B: Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smoothmuscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol 303: H282-H296, 2012
49. Itani HA, Dikalov S, Harrison DG: Knock, knock: Who's there?: Nox1. Circulation 127: 1850-1852, 2013
50. You YH,Okada S, Ly S, Jandeleit-DahmK, BaritD,Namikoshi T, Sharma K: Role of Nox2 in diabetic kidney disease. Am J Physiol Renal Physiol 304: F840-F848, 2013
51. Sedeek M, Montezano AC, Hebert RL, Gray SP, Di Marco E, Jha JC, CooperME, Jandeleit-DahmK, Schiffrin EL,Wilkinson-Berka JL, TouyzRM: Oxidative stress, Nox isoforms and complications of diabetes-potential targets for novel therapies. J Cardiovasc Transl Res 5: 509-518, 2012
52. Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schröder K, Brandes RP, Devaraj S, Török NJ: Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 53: 289-296, 2012
53. Gavazzi G, Banfi B, Deffert C, Fiette L, Schappi M, Herrmann F, Krause KH: Decreased blood pressure in NOX1-deficientmice. FEBS Lett 580: 497-504, 2006
54. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ Jr: Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216: 321-326, 2011
55. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, Page P: First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem53: 7715-7730, 2010
56. Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA: The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53: 192-203, 2010
57. Krege JH, Hodgin JB, Hagaman JR, Smithies O: A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115, 1995
58. Watson AM, Gray SP, Jiaze L, Soro-Paavonen A, Wong B, Cooper ME, Bierhaus A, Pickering R, Tikellis C, Tsorotes D, Thomas MC, Jandeleit-Dahm KA: Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 61: 2105-2113, 2012
59. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC: PPAR-alpha and-gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 21: 2399-2405, 2006
60. SaleemMA,O'HareMJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638, 2002
61. Okabe J,Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, CooperME, El-Osta A: Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res 110: 1067-1076, 2012